Results 151 to 160 of about 15,695 (241)

O32 Impact of patient baseline characteristics on SLE Responder Index-4 (SRI[4]) responses to deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor in the phase 2 PAISLEY trial in systemic lupus erythematosus [PDF]

open access: hybrid
Eric F. Morand   +10 more
openalex   +1 more source

Authigenic mineralization in Surtsey basaltic tuff deposits at 50 years after eruption. [PDF]

open access: yesSci Rep, 2023
Montesano G   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy